Results 261 to 270 of about 428,204 (309)
Some of the next articles are maybe not open access.
2022
Introduction BCR-ABL1-negative classic myeloproliferative neoplasms (MPN) include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Calreticulin (CALR) 52 bp deletion and 5 bp insertion were discovered to be involved in MPN pathogenesis.
Vadeikienė, Roberta +4 more
openaire +1 more source
Introduction BCR-ABL1-negative classic myeloproliferative neoplasms (MPN) include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Calreticulin (CALR) 52 bp deletion and 5 bp insertion were discovered to be involved in MPN pathogenesis.
Vadeikienė, Roberta +4 more
openaire +1 more source
Gan to kagaku ryoho. Cancer & chemotherapy, 2011
PI3K-Akt is an important signal transduction pathway which acts downstream from various growth factor receptors. The PI3K-Akt pathway is activated in many types of cancers by several mechanisms, including growth factor receptor activation, loss of PTEN, and PI3K gene mutations. Therefore, PI3K is thought to be an ideal therapeutic target.
Seiji, Yano +6 more
openaire +1 more source
PI3K-Akt is an important signal transduction pathway which acts downstream from various growth factor receptors. The PI3K-Akt pathway is activated in many types of cancers by several mechanisms, including growth factor receptor activation, loss of PTEN, and PI3K gene mutations. Therefore, PI3K is thought to be an ideal therapeutic target.
Seiji, Yano +6 more
openaire +1 more source
PI3K Inhibitor–Induced Insulin Feedback Activates PI3K Signaling
Cancer Discovery, 2018Abstract Hyperinsulinemia drives resistance to PI3Kα inhibitors in tumors.
openaire +1 more source
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
International Journal of Molecular Sciences, 2021Rosalin Mishra +2 more
exaly
PI3K inhibitors are finally coming of age
Nature Reviews Drug Discovery, 2021Fabrice André +2 more
exaly
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
Acta Pharmaceutica Sinica B, 2022Qinjie Weng, Jiajia Wang, Jincheng Wang
exaly
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Seminars in Cancer Biology, 2022Pengda Liu
exaly